Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 2 de 2
Add filters

Year range
Article in Chinese | WPRIM | ID: wpr-872968


Objective::To screen out active ingredients of Polygonati Rhizoma-Lilii Bulbus, and predict the targets and signaling pathways, in order to explore the potential mechanism in treatment of cancer by using network pharmacology. Method::All of active ingredients and targets of Polygonati Rhizoma-Lilii Bulbus were screened out through the Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform (TCMSP). Disease targets for cancer were collected through databases of gene-disease associations (DisGeNET) and Online Mendelian Inheritance in Man (OMIM). Then the Omicshare platform was used to match the active ingredients and the targets for treating cancer. And the " drug-active ingredients-disease targets" network was established using Cytoscape 3.7.0 software. The functional protein association networks (String) database was used to construct the protein interaction network of drug pair targets for treating cancer. Finally, the Functional Annotation Bioinformatics Microarray Analysis (DAVID) database was used to analyze the biological functions and metabolic pathways of key targets. Result::A total of 19 active ingredients were screened out, 234 targets were predicted, 6 active ingredients were identified to be related to cancer. The anti-cancer effect was mainly correlated with the regulation of target proteins in treating cancer, such as Akt serine/threonine kinase 1 (Akt1), Jun proto-oncogene, AP-1 transcription factor subunit (JUN), vascular endothelial growth factor A (VEGFA), matrix metallopeptidase-9 (MMP-9), Caspase-3, Fos proto-oncogene, AP-1 transcription factor subunit (FOS), proteoglycans in cancer, estrogen signaling pathway, human immunodeficiency virus 1 infection, hypoxia inducible factor-1 (HIF-1) signaling pathway, tumor necrosis factor(TNF) signaling pathway, microRNAs in cancer and other pathways. Conclusion::The anti-cancer effect of Polygonati Rhizoma-Lilii Bulbus reflects multi-component, multi-target, multi-pathway characteristics of TCM, and provides a scientific basis for explaining the mechanism and material basis of anti-cancer treatment.

Article in Chinese | WPRIM | ID: wpr-707167


Objective To explore the medication features of Professor LIU Shang-yi for the treatment of hepatocarcinoma; To provide references for the clinic. Methods Medical cases about hepatocarcinoma treated by Professor LIU Shang-yi in National Medical Center Clinic of Guizhou Provincial TCM Hospital from March 2014 to August 2016 were collected. TCM inheritance support platform software V2.5 was used to analyze properties and flavors, frequency, compatibility law and core medicine combinations. Results Totally 318 prescriptions were included in the study, involving 137 kinds of Chinese materia medica and frequency of 2931 times. The medicines with high frequency were Curcumae Rhizoma, vinegar Trionycis Carapax, Rabdosiae Rubescentis Herba, Ranunculi Ternati Radix and Hypericum Japonicum Thunb; cold and warm were used in the prescriptions, and there were a lot of medicines with flavors of spicy, bitter and sweet. 68 groups of two medicines, 100 groups of three medicines and 72 groups of four medicines with high frequency were obtained by data mining. High frequency association rules were"Curcumae Rhizoma - vinegar Trionycis Carapax", "Curcumae Rhizoma - Rabdosiae Rubescentis Herba", "vinegar Trionycis Carapax - Rabdosiae Rubescentis Herba". Conclusion The prescriptions for the treatment of hepatocarcinoma by Professor LIU Shang-yi have the efficacy of tonifying yin, and resolving masses, clearing heat and detoxifying, which shows the treatment principles of strengthening body resistance and eliminating evil, and adjusting yin and yang.